|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (SL-401) is a CD123-targeted therapy consisting of interleukin-3 fused to a truncated diphtheria toxin payload.
|
31437130 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (SL401, Stemline Therapeutics), a recombinant protein composed of a truncated diphtheria toxin payload fused to IL-3, was approved for use in patients with BPDCN in December of 2018 and showed some clinical activity in AML.
|
31547472 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
30859413 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interleukin 3 receptor (CD123) is a transmembrane protein that is absent or hardly expressed on normal hematopoietic stem cells, but highly expressed on the surface of cancer cells in several hematologic malignancies.In this issue of the JCI, Togami et al. investigated the mechanism of resistance to the recently approved anti-CD123 agent tagraxofusp, which consists of interleukin 3 fused to a truncated diphtheria toxin (DT) molecule.
|
31609247 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin.
|
31018069 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp is an intravenously administered CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload and was recently approved by the Food and Drug Administration for the treatment of adults and children aged 2 and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31465247 |
2019 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report indiscriminate killing of CD123<sup>+</sup> normal and acute myeloid leukemia / myelodysplastic syndrome cells by SL-401, a diphtheria toxin interleukin-3 fusion protein.
|
29773600 |
2018 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL3) would improve the effectiveness of TKIs against Ph(+) AL cells.
|
20137810 |
2010 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
|
16489085 |
2006 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
A genetically engineered fusion toxin targeted to acute myeloid leukemia (AML) blasts was designed with the first 388 amino acid residues of diphtheria toxin with an H-M linker fused to human interleukin-3.
|
14680969 |
2004 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of cytosine arabinoside (Ara-C) to truncated diphtheria toxin (DT388) fused to granulocyte macrophage-colony stimulating factor (GMCSF) or interleukin-3 (IL3) was studied in a NOD/SCID mouse model of human AML.
|
15380349 |
2004 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cells recovered from leukemic animals continued to express interleukin-3 receptors and remained sensitive to the diphtheria fusion protein DT388IL3.
|
11368443 |
2001 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors.
|
10764142 |
2000 |